Manufacture and immunogenicity of therapeutic RNA Hepatitis C Virus genotype 4 vaccine by bio-informatics | ||||
| International Journal of Health Sciences (Egypt) | ||||
| Articles in Press, Accepted Manuscript, Available Online from 02 August 2023 | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/ijhegy.2023.206469.1026 | ||||
 View on SCiNiTO | ||||
| Author | ||||
Mohammed M Kassab  
| ||||
| Instructor of microbiology,immunology,faculty of pharmacy,Cairo university,Egypt Specialist of pharmacology, toxicology and clinical pharmacy. | ||||
| Abstract | ||||
| Background: Hepatitis C is a very hazardous health difficulty these days. Infection is usually restricted to the hepatocytes. Due to the rapid mutation rate of the Hepatitis C virus, immunity lasts a long time and reinfection occurs (HCV). People infected with HCV develop chronic hepatitis, cirrhosis, and liver cancer. It is believed that more than 2% of the world's population is afflicted with HCV, a blood-borne and sexually transmitted illness. At the moment, two types of HCV vaccines are being studied: prophylactic vaccinations to prevent infection and therapeutic vaccines to treat and prevent disease progression to cirrhosis and liver cancer. Because direct acting anti-HCV medicines have a limited function in infection control, it is required to develop preventive and therapeutic vaccines to address this issue. The aim of the study: Bio-informatics is being used to develop a therapeutic mRNA vaccination against HCV. Type of study Screening experimental examination. Methodology: In the present study, bionformactics were used to create a lipid nanoparticles RNA vaccination comprising nonstructural NS2 transmembrane protein, highly conserved nonstructural NS3 and NS4A proteins. The lipid nanoparticles vaccine delivery method was devised with a particle size of around 65 nm. Immunogenicity studies were carried out at the animal testing stage, followed by phases 1/2 of clinical trials. Results: The therapeutic RNA vaccine demonstrated 65% effectiveness in preclinical studies and 60% efficacy in human clinical trials stages 1 and 2. It had higher biological activity and fewer adverse effects than other conventional vaccinations currently being tested in clinical studies. | ||||
| Keywords | ||||
| Hepatitis; RNA vaccine; virus; infection | ||||
|
Statistics Article View: 27 |
||||
